{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:04:51Z","timestamp":1790129091333,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neurot.2026.e00974","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:32:27Z","timestamp":1785155547000},"page":"e00974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of a CI-994 derivative as a dual modulator of class I histone deacetylases and Wnt\/\u03b2-catenin signaling for Alzheimer\u2019s disease therapy"],"prefix":"10.1016","volume":"23","author":[{"given":"Wenyan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Caulfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunmi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suren","family":"Jeevaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Kanekiyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neurot.2026.e00974_bib1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"issue":"s1","key":"10.1016\/j.neurot.2026.e00974_bib2","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.3233\/JAD-179921","article-title":"Multifactorial hypothesis and multi-targets for Alzheimer\u2019s disease","volume":"64","author":"Gong","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00974_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurot.2026.e00974_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.conb.2020.08.011","article-title":"Cognitive epigenetic priming: leveraging histone acetylation for memory amelioration","volume":"67","author":"Burns","year":"2021","journal-title":"Curr Opin Neurobiol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00974_bib5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1021\/acschemneuro.1c00775","article-title":"Histone deacetylases 1 and 2 in memory function","volume":"13","author":"Pao","year":"2022","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/1570159X19666210609160017","article-title":"Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: current targets and future perspective","volume":"20","author":"Kumar","year":"2022","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.neurot.2026.e00974_bib7","article-title":"The role of altered protein acetylation in neurodegenerative disease","volume":"14","author":"Kabir","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00974_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13895","article-title":"Reduction of class I histone deacetylases ameliorates ER-mitochondria cross-talk in Alzheimer\u2019s disease","volume":"22","author":"Marinho","year":"2023","journal-title":"Aging Cell"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00974_bib9","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/npp.2009.197","article-title":"Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer\u2019s disease","volume":"35","author":"Kilgore","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00974_bib10","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/npp.2015.93","article-title":"Pharmacological selectivity within class I histone deacetylases predicts effects on synaptic function and memory rescue","volume":"40","author":"Rumbaugh","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00974_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054805","article-title":"Selective targeting of class I HDAC reduces microglial inflammation in the entorhinal cortex of young APP\/PS1 mice","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00974_bib12","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1021\/acschemneuro.8b00116","article-title":"Class I histone deacetylase inhibition by tianeptinaline modulates neuroplasticity and enhances memory","volume":"9","author":"Zhao","year":"2018","journal-title":"ACS Chem Neurosci"},{"issue":"38","key":"10.1016\/j.neurot.2026.e00974_bib13","doi-asserted-by":"crossref","first-page":"13124","DOI":"10.1523\/JNEUROSCI.0914-15.2015","article-title":"Histone deacetylase inhibition via RGFP966 releases the brakes on sensory cortical plasticity and the specificity of memory formation","volume":"35","author":"Bieszczad","year":"2015","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13195-026-01982-0","article-title":"CI-994 is a dual modulator of class I HDACs and Wnt\/beta-catenin signaling for the treatment of Alzheimer\u2019s disease","volume":"18","author":"Lu","year":"2026","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13041-019-0525-5","article-title":"Restoring Wnt\/beta-catenin signaling is a promising therapeutic strategy for Alzheimer\u2019s disease","volume":"12","author":"Jia","year":"2019","journal-title":"Mol Brain"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00974_bib16","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/annonc\/mdl081","article-title":"Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study","volume":"17","author":"Richards","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.critrevonc.2008.03.002","article-title":"The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer","volume":"68","author":"Gridelli","year":"2008","journal-title":"Crit Rev Oncol-Hematol"},{"key":"10.1016\/j.neurot.2026.e00974_bib18","series-title":"Chapter 8 - epigenetic Therapy of Cancer. Medicinal chemistry of anticancer drugs","first-page":"389","author":"Avendano","year":"2023"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00974_bib19","first-page":"994","article-title":"Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate","volume":"6","author":"Riva","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"1-2","key":"10.1016\/j.neurot.2026.e00974_bib20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cell.2013.12.020","article-title":"Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories","volume":"156","author":"Graff","year":"2014","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00974_bib21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41419-018-0543-8","article-title":"Class I histone deacetylase (HDAC) inhibitor CI-994 promotes functional recovery following spinal cord injury","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41467-019-13918-4","article-title":"Inhibition of histone deacetylation rescues phenotype in a mouse model of Birk-Barel intellectual disability syndrome","volume":"11","author":"Cooper","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2026.e00974_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.674745","article-title":"Dose effects of histone deacetylase inhibitor tacedinaline (CI-994) on antipsychotic Haloperidol-induced motor and memory side effects in aged mice","volume":"15","author":"McClarty","year":"2021","journal-title":"Front Neurosci"},{"issue":"22","key":"10.1016\/j.neurot.2026.e00974_bib24","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116797119","article-title":"The HDAC inhibitor CI-994 acts as a molecular memory aid by facilitating synaptic and intracellular communication after learning","volume":"119","author":"Burns","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"issue":"56","key":"10.1016\/j.neurot.2026.e00974_bib25","doi-asserted-by":"crossref","first-page":"9129","DOI":"10.1038\/sj.onc.1208123","article-title":"LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution","volume":"23","author":"Li","year":"2004","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.neurot.2026.e00974_bib26","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.febslet.2011.08.046","article-title":"Mesd is a general inhibitor of different Wnt ligands in Wnt\/LRP signaling and inhibits PC-3 tumor growth in vivo","volume":"585","author":"Lin","year":"2011","journal-title":"FEBS Lett"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00974_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029290","article-title":"Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt\/beta-catenin pathway","volume":"6","author":"Lu","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00974_bib28","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/0006-2952(94)90520-7","article-title":"Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance","volume":"47","author":"Houston","year":"1994","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00974_bib29","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/dmd.105.005421","article-title":"Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity","volume":"33","author":"Taub","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00974_bib30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.vascn.2014.08.002","article-title":"Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations","volume":"70","author":"Jin","year":"2014","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00974_bib31","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1055\/s-2007-967137","article-title":"Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: in vitro models for intestinal and blood-brain barrier permeability","volume":"73","author":"Madgula","year":"2007","journal-title":"Planta Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib32","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1038\/s41467-020-19264-0","article-title":"APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer\u2019s disease patient iPSC-derived cerebral organoids","volume":"11","author":"Zhao","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00974_bib33","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00401-021-02361-9","article-title":"Apolipoprotein E regulates lipid metabolism and alpha-synuclein pathology in human iPSC-derived cerebral organoids","volume":"142","author":"Zhao","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00974_bib34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3233\/JAD-230218","article-title":"Upregulation of sFRP1 is more profound in female than Male 5xFAD mice and positively associated with amyloid pathology","volume":"95","author":"Macyczko","year":"2023","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12035-022-03065-1","article-title":"Suppression of Wnt\/beta-Catenin signaling is associated with downregulation of Wnt1, PORCN, and Rspo2 in Alzheimer\u2019s disease","volume":"60","author":"Macyczko","year":"2023","journal-title":"Mol Neurobiol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00974_bib36","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1158\/1535-7163.MCT-13-0555","article-title":"Effect of niclosamide on basal-like breast cancers","volume":"13","author":"Londono-Joshi","year":"2014","journal-title":"Mol Cancer Therapeut"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ygyno.2014.04.005","article-title":"Inhibition of Wnt\/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer","volume":"134","author":"Arend","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00974_bib38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/03602532.2021.1970178","article-title":"Drug metabolic stability in early drug discovery to develop potential lead compounds","volume":"53","author":"Gajula","year":"2021","journal-title":"Drug Metab Rev"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.932","article-title":"Application of a high-resolution in vitro human MDR1-MDCK assay and in vivo studies in preclinical species to improve prediction of CNS drug penetration","volume":"10","author":"Jiang","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12987-023-00495-4","article-title":"Application of a new MDCKII-MDR1 cell model to measure the extent of drug distribution in vitro at equilibrium for prediction of in vivo unbound brain-to-plasma drug distribution","volume":"21","author":"Langthaler","year":"2024","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.neurot.2026.e00974_bib41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.brainres.2015.10.005","article-title":"Induced pluripotent stem cells as a discovery tool for Alzheimers disease","volume":"1656","author":"Sullivan","year":"2017","journal-title":"Brain Res"},{"key":"10.1016\/j.neurot.2026.e00974_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146803","article-title":"Human organoids to model the developing human neocortex in health and disease","volume":"1742","author":"Khakipoor","year":"2020","journal-title":"Brain Res"},{"key":"10.1016\/j.neurot.2026.e00974_bib43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.semcdb.2020.05.024","article-title":"The future of cerebral organoids in drug discovery","volume":"111","author":"Salick","year":"2021","journal-title":"Semin Cell Dev Biol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00974_bib44","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/nn.2360","article-title":"Wnt-mediated activation of NeuroD1 and retro-elements during adult neurogenesis","volume":"12","author":"Kuwabara","year":"2009","journal-title":"Nat Neurosci"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00974_bib45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","article-title":"Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies","volume":"15","author":"Yamazaki","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00974_bib46","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat Neurosci"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00974_bib47","doi-asserted-by":"crossref","first-page":"16489","DOI":"10.1007\/s12035-025-05264-y","article-title":"Histone deacetylase 2 in Alzheimer\u2019s Disease: a comprehensive molecular blueprint for therapeutic targeting","volume":"62","author":"Asadi","year":"2025","journal-title":"Mol Neurobiol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00974_bib48","doi-asserted-by":"crossref","first-page":"9573","DOI":"10.1007\/s12035-025-04866-w","article-title":"HDAC3 as an emerging therapeutic target for Alzheimer\u2019s disease and other neurological disorders","volume":"62","author":"Li","year":"2025","journal-title":"Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00974_bib49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/jnc.14309","article-title":"Complex neuroprotective and neurotoxic effects of histone deacetylases","volume":"145","author":"Thomas","year":"2018","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuron.2014.08.048","article-title":"Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer\u2019s disease","volume":"84","author":"Liu","year":"2014","journal-title":"Neuron"},{"issue":"22","key":"10.1016\/j.neurot.2026.e00974_bib51","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.1073\/pnas.0603523104","article-title":"Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer\u2019s disease","volume":"104","author":"De Ferrari","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00974_bib52","doi-asserted-by":"crossref","first-page":"1709 e9","DOI":"10.1016\/j.neurobiolaging.2012.11.004","article-title":"A novel functional low-density lipoprotein receptor-related protein 6 gene alternative splice variant is associated with Alzheimer\u2019s disease","volume":"34","author":"Alarcon","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00974_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo7421","article-title":"A genetic variant of the Wnt receptor LRP6 accelerates synapse degeneration during aging and in Alzheimer\u2019s disease","volume":"9","author":"Jones","year":"2023","journal-title":"Sci Adv"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00974_bib54","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nn.2333","article-title":"HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction","volume":"12","author":"Ye","year":"2009","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.stem.2015.05.016","article-title":"TPO-induced metabolic reprogramming drives liver metastasis of colorectal cancer CD110+ tumor-initiating cells","volume":"17","author":"Wu","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00974_bib56","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1091\/mbc.e16-07-0547","article-title":"NLK-mediated phosphorylation of HDAC1 negatively regulates Wnt signaling","volume":"28","author":"Masoumi","year":"2017","journal-title":"Mol Biol Cell"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s11658-021-00305-5","article-title":"The interaction of canonical Wnt\/beta-catenin signaling with protein lysine acetylation","volume":"27","author":"You","year":"2022","journal-title":"Cell Mol Biol Lett"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00974_bib58","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1074\/jbc.M114.620872","article-title":"p15RS\/RPRD1A (p15INK4b-related sequence\/regulation of nuclear pre-mRNA domain-containing protein 1A) interacts with HDAC2 in inhibition of the Wnt\/beta-catenin signaling pathway","volume":"290","author":"Liu","year":"2015","journal-title":"J Biol Chem"},{"issue":"18","key":"10.1016\/j.neurot.2026.e00974_bib59","doi-asserted-by":"crossref","first-page":"6882","DOI":"10.1128\/MCB.20.18.6882-6890.2000","article-title":"Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator","volume":"20","author":"Billin","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03508-0","article-title":"Inhibition of class I HDACs preserves hair follicle inductivity in postnatal dermal cells","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00974_bib61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.stem.2013.12.001","article-title":"In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer\u2019s disease model","volume":"14","author":"Guo","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib62","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41467-020-14855-3","article-title":"Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington\u2019s disease","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib63","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ymthe.2019.09.003","article-title":"A NeuroD1 AAV-based gene therapy for functional brain repair after ischemic injury through in vivo astrocyte-to-neuron conversion","volume":"28","author":"Chen","year":"2020","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00974_bib64","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12974-023-02949-w","article-title":"NeuroD1 administration ameliorated neuroinflammation and boosted neurogenesis in a mouse model of subarachnoid hemorrhage","volume":"20","author":"Chen","year":"2023","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00974_bib65","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.102.039255","article-title":"Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs","volume":"303","author":"Mahar","year":"2002","journal-title":"J Pharmacol Exp Therapeut"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:10:04Z","timestamp":1790125804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926001443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1878747926001443"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00974","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a CI-994 derivative as a dual modulator of class I histone deacetylases and Wnt\/\u03b2-catenin signaling for Alzheimer\u2019s disease therapy","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00974"}}